On November 6, 2025, the Trump administration announced new pricing and coverage agreements with Eli Lilly and Novo Nordisk for widely used glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro®, Zepbound®) and semaglutide (Ozempic®, Wegovy®). These agreements aim to lower out-of-pocket costs for some patients and expand access under federal health programs beginning in 2026. […]
